![]() |
|
|
Vol. 58, Issue 2, 271-278, August 2000
Committee on Neurobiology (K.N., R.J.M., U.J.K.), Departments of Neurology (D.A.W., U.J.K.), Neurobiology, Pharmacology & Physiology (V.P.B., R.J.M., U.J.K.), Pediatrics (J.D.M., D.M.F.), and Surgery (D.M.F.), The University of Chicago, Chicago, Illinois
| |
Abstract |
|---|
|
|
|---|
1-Methyl-4-phenylpyridinium (MPP+) is selectively toxic to
dopaminergic neurons and has been studied extensively as an etiologic model of Parkinson's disease (PD) because mitochondrial dysfunction is
implicated in both MPP+ toxicity and the pathogenesis of
PD. MPP+ can inhibit mitochondrial complex I activity, and
its toxicity has been attributed to the subsequent mitochondrial
depolarization and generation of reactive oxygen species. However,
MPP+ toxicity has also been noted to be greater than
predicted by its effect on complex I inhibition or reactive oxygen
species generation. Therefore, we examined the effects of
MPP+ on survival, mitochondrial membrane potential
(
m), and superoxide and reduced glutathione levels in individual
dopaminergic and nondopaminergic mesencephalic neurons.
MPP+ (5 µM) selectively induced death in fetal rat
dopaminergic neurons and caused a small decrease in their 
m. In
contrast, the specific complex I inhibitor rotenone, at a dose (20 nM)
that was less toxic than MPP+ to dopaminergic neurons,
depolarized 
m to a greater extent than MPP+. In
addition, neither rotenone nor MPP+ increased superoxide in
dopaminergic neurons, and MPP+ failed to alter levels of
reduced glutathione. Therefore, we conclude that increased superoxide
and loss of 
m may not represent primary events in
MPP+ toxicity, and complex I inhibition alone is not
sufficient to explain the selective toxicity of MPP+ to
dopaminergic neurons. Clarifying the effects of MPP+ on
energy metabolism may provide insight into the mechanism of dopaminergic neuronal degeneration in PD.
| |
Introduction |
|---|
|
|
|---|
A
combination of mitochondrial dysfunction and increased oxidative stress
is hypothesized to contribute to the selective degeneration of
nigrostriatal dopaminergic neurons in Parkinson's disease (PD; Jenner
and Olanow, 1996
). The neurotoxin
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is selectively
toxic to the nigrostriatal dopaminergic system and has been studied
extensively as an etiologic model for PD. MPTP is oxidized by monoamine
oxidase B to 1-methyl-4-phenylpyridinium (MPP+;
Langston et al., 1984
), which is imported into dopaminergic neurons via
the dopamine transporter (Javitch et al., 1985
).
MPP+ accumulates in mitochondria (Ramsay and
Singer, 1986
), and high concentrations of MPP+
partially inhibit mitochondrial complex I activity, resulting in
mitochondrial depolarization and decreased levels of ATP and glutathione in various nondopaminergic cell types (Nicklas et al.,
1985
; Di Monte et al., 1987
; Mizuno et al., 1987a
). High concentrations
of MPP+ also increase superoxide levels in
isolated mitochondria (Hasegawa et al., 1990
). Superoxide has been
hypothesized to interact with nitric oxide (NO) to produce
peroxynitrate and cell death (Przedborski et al., 1996
). Superoxide
dismutase (SOD) converts superoxide to
H2O2, which is then
metabolized to H2O by glutathione peroxidase, or
catalase. MPP+ toxicity in vivo is reduced after
overexpression of the cytosolic copper/zinc form of SOD (Cu/Zn-SOD;
Przedborski et al., 1992
). In addition, a significant role for the
glutathione system in detoxifying MPP+-induced
oxidative stress is suggested by the findings that glutathione depletion synergistically increases MPP+ toxicity
both in vitro (Nakamura et al., 1997
) and in vivo (Wullner et al.,
1996
).
On the other hand, other investigators have noted that
MPP+ toxicity may not be primarily due to complex
I inhibition or reactive oxygen species (ROS) generation (Bates et al.,
1994
; Espino et al., 1994
). MPP+ typically
produces 104- to 106-fold
less complex I inhibition than rotenone (Mizuno et al., 1987b
; Hasegawa
et al., 1990
; Ramsay et al., 1991
), a specific and potent inhibitor of
complex I (Hartley et al., 1994
). The toxicity of
MPP+ and its effect on energy depletion are also
out of proportion to its effect on complex I inhibition (Bates et al.,
1994
; Espino et al., 1994
). The lack of significant protection by
antioxidants or specific NO synthase inhibitors (Sanchez-Ramos et al.,
1988
, 1997
; Choi et al., 1999
; Di Monte et al., 1999
; Lotharius et al., 1999
; Royland et al., 1999
) also casts doubt on the significance of
oxidative stress as an instigator of MPP+-induced
cell death.
In this study, we sought direct evidence for the effects of
MPP+ on mitochondrial function and ROS production
in individual living mesencephalic neurons. Changes in mitochondrial
membrane potential (
m) and superoxide and reduced glutathione
levels (GSH) were examined in dopaminergic and nondopaminergic neurons
identified by subsequent immunohistochemistry. We also compared the
effects of MPP+ with those of rotenone to
determine whether the inhibition of mitochondrial complex I is
sufficient to explain the selective dopaminergic neurotoxicity of
MPP+.
| |
Experimental Procedures |
|---|
|
|
|---|
Materials. Timed pregnant Sprague-Dawley rats were purchased from Harlan Sprague-Dawley (Madison, WI). Dulbecco's modified Eagle's medium (DMEM) and Hanks' balanced salt solution (HBSS) were obtained from Life Technologies (Grand Island, NY). Fetal bovine serum was obtained from Intergen (Purchase, NY). Trypsin was purchased from Worthington Biochemical Corporation (Freehold, NJ). Dimethyl sulfoxide (DMSO) and Hemo-De were obtained from Fisher (Itasca, IL). MPP+ iodide was obtained from Research Biochemical Internationals (Natick, MA). Glass coverslips were purchased from Carolina Biological (Burlington, NC). DNase, L-buthionine-[S,R]sulfoximine (BSO), benzidine dihydrochloride, 3,3'-diaminobenzidine tetrahydrochloride (DAB), 5-fluoro-2-deoxyuridine, Triton X-100, sodium nitroprusside dihydrate, rotenone, carbonyl cyanide p-trifluoromethoxy-phenylhydrazone (FCCP), BSA, and mouse monoclonal antibody against neurofilament protein 200 (NFP) were purchased from Sigma Chemical Co. (St. Louis, MO). Monochlorobimane (MCB), hydroethidine (HEt), 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanine iodide (JC-1), and ProLong Antifade Kit were obtained from Molecular Probes (Eugene, OR). Rabbit polyclonal antibody against tyrosine hydroxylase (TH) was obtained from Pel-Freez (Rogers, AR). Mouse monoclonal antibody against neuron-specific nuclear protein was obtained from Chemicon (Temecula, CA). Cy2-conjugated streptavidin was purchased from Jackson ImmunoResearch Laboratories (West Grove, PA). Biotinylated anti-rabbit IgG and Vectastain ABC kit were obtained from Vector Laboratories (Burlingame, CA).
Cell Cultures. All animal experiments were approved by the Institutional Animal Care and Use Committee at the University of Chicago and were conducted in accordance with National Institutes of Health guidelines for care and use of experimental animals. Rodents were maintained in standard housing. Pieces of ventral mesencephalon, dissected from embryonic gestation day 14 rat embryos, were incubated for 20 min at 37°C in 0.4% trypsin in calcium- and magnesium-free HBSS and triturated 8 to 10 times in 0.015% DNase using flame-polished Pasteur pipettes. Cell number and viability were determined with trypan blue staining using a hemocytometer. Cells were plated onto poly(L-lysine)-coated glass coverslips at a density of 200,000 viable cells/cm2. Cells were grown in high glucose DMEM supplemented with 10% fetal bovine serum. After 48 h, medium was changed to DMEM containing 10% fetal bovine serum and 10 µg/ml 5-fluoro-2-deoxyuridine to inhibit glial growth, and cells were grown an additional 4 to 6 days before study. Glia represented less than 15% of the total cells in the culture, based on the number of cells that lacked immunoreactivity to NFP or neuron-specific nuclear protein antibodies.
Toxicity Studies. Cells were exposed to experimental compounds (added as 3× stocks) for 24 or 48 h, at which time cell survival was quantified. Rotenone and staurosporine were prepared in DMSO, before dilution in medium. The final concentration of DMSO was 28 µM, and this concentration of DMSO did not affect any of the parameters examined (data not shown). In experiments examining the time course of dopaminergic cell death, cells were incubated in the presence or absence of MPP+ (5 µM) for 24 h, at which time media were changed and cells were treated for an additional 24 h with or without MPP+. To control for conditioning of the media by the cells and degradation of MPP+ during the incubation, media used for the second 24-h incubation period were taken from parallel cultures that had already been incubated with the media for 24 h.
Immunohistochemistry. TH immunoreactivity was used as an unambiguous way of identifying dopaminergic neurons, by use of post hoc matching of fluorescent microscopic images (see later) with immunohistochemical data. Cells were fixed in 4% paraformaldehyde/0.1 M phosphate buffer for 15 min. Endogenous peroxidase activity was removed by exposing cells to 0.6% H2O2 in 0.1 M PBS for 15 min. Cells were permeabilized, and nonspecific antibody binding was blocked by incubation in PBS containing 1% BSA and 0.2% Triton X-100 for 30 min. Cells were then incubated at room temperature overnight in either primary polyclonal anti-TH antiserum (1:1000) or primary monoclonal anti-NFP antibody (1:200). Cultures were next incubated for 1 h with the appropriate biotinylated secondary antibody (1:200). This was followed by a 1-h incubation with an avidin-biotin conjugate of peroxidase (Vectastain ABC kit). Benzidine dihydrochloride or DAB was used as chromogens for immunoperoxidase staining. Coverslips were dehydrated with graded ethanol washes followed by Hemo-De.
Quantification of Toxin-Induced Death.
After treatment with
MPP+, rotenone, or control media, the number of
surviving dopaminergic and nondopaminergic neurons were counted based
on morphologic criteria using a protocol similar to that described
previously (Nakamura et al., 1997
). Briefly, a grid containing 12 squares was placed under the coverslip, and surviving cells were
counted from a defined field in the center of each of the 12 squares.
Cells were defined as surviving if they had intact cell bodies and
neurites. Cells exhibiting fragmented or atrophic cell bodies, or loss
or disruption of neurites, were not counted. The number of surviving
neurons in each field was recorded in both experimental and control
groups. Survival in a particular condition was calculated by dividing
the number of surviving cells in each field by the mean of the control
group, expressed as a percent. We sampled approximately 1% of the
total coverslip area when counting NFP-immunoreactive, TH-negative
nondopaminergic neurons. Because dopaminergic neurons make up
approximately 5 to 10% of total neurons in the culture, we sampled
approximately 10% of the total coverslip area when counting
TH-immunoreactive dopaminergic neurons. All counting was blind to the
incubation condition and made at a magnification of 400×.
Measurement of 
m.
Changes in 
m were estimated
using the dual emission dye JC-1 (Salvioli et al., 1997
). As a monomer,
JC-1 emits green light, but the emission changes to red when JC-1
aggregates form as JC-1 concentrates within the mitochondria. JC-1
stock (5 mM) in DMSO was diluted in media to a final concentration of
10 µM, sonicated for 30 s, and filtered through a 0.2-µm
filter into a glass container. Cells were loaded for 60 min in JC-1 at
37°C in the dark and then rinsed before being placed in a chamber on
the stage of an inverted microscope at room temperature. Within a given
field, regions of interest were drawn over all cells with intact
somata, regardless of their neurite morphology. Neurons growing on top
of glia were excluded from physiology measurements. Neurons were
alternately subjected to Xe epifluorescence illumination (attenuated
with a 2.0 neutral density filter) for fluorescence imaging and halogen transmitted illumination for differential interference contrast (DIC)
imaging. Images were formed with a 40×, 1.25 NA objective and
collected with a cooled CCD camera (Photometrics, Tucson, AZ). Neurons
were excited with 488-nm light, and the emitted fluorescence was
sequentially imaged at 530 and 620 nm using a triple-bandpass polychroic mirror and single-wavelength emission filters (83000 series;
Chroma Technology, Brattleboro, VT) and a computer-controlled filter
wheel located in front of the camera. The DIC analyzer was located in
the emission filter wheel. Images were acquired using Metafluor
software (Universal Imaging Corp., West Chester, PA) and stored in
digital format on a random access device. Within each region of
interest, ratios of fluorescence from aggregates to that from monomers
(JC-1 ratio) were calculated on a pixel-by-pixel basis, and the average
of the JC-1 ratios over the entire region was used as an estimate of

m for the neuron.
Measurement of Superoxide.
The rate of increase in ethidium
(Et) fluorescence when HEt is oxidized provides a relatively specific
measure of superoxide (Bindokas et al., 1996
). Fluorescence
measurements were made with a Nikon Diaphot epifluorescence microscope
with illumination from a 150-W Xe arc (attenuated by a neutral density
1.5, ultraviolet-grade filter; Omega Optical, Brattleboro, VT). Et
imaging used standard rhodamine optics (excitation 510-560 nm;
dichroic mirror 580 nm; emission >590 nm; Nikon, Melville, NY). Images
were formed using a 40× Fluor NA 0.85 objective (Nikon) and collected
on a Hamamatsu ICCD (sensitivity set at 7.0). Images were 8-bit (256 intensity levels), and 16 frames were averaged every 10 s.
Background subtraction was made using the first image obtained when HEt
solution was added and, in addition, from a cell-free region of the
field to track subsequent changes in background. Data acquisition was
controlled by MetaFluor or MetaMorph software (Universal Imaging
Corp.), and average intensity over identified regions of interest was logged to hard disk and displayed in real time. The relative superoxide level for each cell was determined from the slope of the increase in Et
fluorescence over time, fit by linear regression. HEt was freshly
prepared and used at a final concentration of 3.2 µM.
Measurement of GSH.
Levels of GSH were determined using MCB
fluorescence. GSH is specifically conjugated with MCB to form a
fluorescent bimane-GSH adduct, in a reaction catalyzed by glutathione
S-transferases (Shrieve et al., 1988
). This conjugation
reaction proceeds according to a first-order kinetic reaction and is
followed by a second kinetic process that is many orders of magnitude
slower and is thought to reflect the nonenzymatic reaction of MCB with
other intracellular thiols (Shrieve et al., 1988
; Young et al., 1994
). As has been described previously (Young et al., 1994
), the
concentration of the bimane-GSH adduct increased during the initial 10 to 12 min period with first order kinetics, before leveling off. By 15 min, BSO treatments no longer affected the slope of increase in
fluorescence (data not shown), confirming that the first order kinetic
phase was finished. Therefore, the fluorescence at 15 min was used as
an indication of the intracellular GSH content, as has been described
previously in similar paradigms (Shrieve et al., 1988
). Imaging
parameters with MCB were the same as described for Et above, except for
the filters used (excitation <400 nm; dichroic mirror 410-430 nm;
emission 440-500 nm). MCB stock (100 mM) was made in DMSO and diluted
to 100 µM before imaging studies. Neurons growing on top of glia were
excluded, because the high fluorescence of GSH in glia overwhelmed the
neuronal signal.
Post Hoc Identification of Dopaminergic Neurons. After each study, the location of the field of cells from which fluorescence measurements were made was marked. Coverslips were then processed for TH immunohistochemistry, and the original field was relocated. Bright field images of the TH staining were obtained with a cooled CCD camera and displayed on a computer monitor overlaid with the original DIC images from that same field. The orientation and location of stained cells were brought into register with the DIC images, then neurons were identified as dopaminergic or nondopaminergic based on immunostaining.
Statistical Analysis. Statistical analyses were performed using the GB-STAT statistical package. Standard errors were calculated for each mean, and statistical differences between groups were determined by ANOVA followed by Newman-Keuls post hoc tests. One-way randomized ANOVA was used for cell counts and imaging studies performed 24 h after treatment, whereas one-way ANOVA with repeated measures was used for superoxide studies examining acute drug effects.
| |
Results |
|---|
|
|
|---|
MPP+ Is Selectively Toxic to Dopaminergic Neurons and
Rotenone Is Not.
We first established a paradigm in which
MPP+ is selectively toxic to dopaminergic
mesencephalic neurons by examining the toxicity of MPP+ at
doses of 1, 5, and 10 µM. Treatment with 5 µM
MPP+ for 48 h resulted in the death of more
than 60% of dopaminergic neurons without significantly affecting the
number of nondopaminergic mesencephalic neurons (Fig.
1). Thus, this dose of MPP+
was selectively toxic to dopaminergic neurons. We next compared the
toxicity of MPP+ with that induced by rotenone, a
specific and potent complex 1 inhibitor. We tested rotenone at doses of
10, 15, 20, 30, 50, and 100 nM to find a dose that is comparably toxic
to dopaminergic neurons. Treatment with rotenone (20 nM) for 48 h
resulted in the nonselective loss of approximately 40% of dopaminergic
and nondopaminergic neurons (Fig. 1).
|
Time Course of Cell Death Induced by MPP+.
To
establish a time point for subsequent imaging studies when active
processes leading to MPP+-induced cell death were
present, we examined whether there were dopaminergic neurons that were
still living at 24 h but were already committed to die by 48 h. We incubated cultures in the presence or absence of
MPP+ (5 µM) for two consecutive 24-h periods
(Table 1). All three groups incurred
significantly more cell death than treatment with control media during
both 24-h periods. Treatment with MPP+ for both
24-h periods (MPP+/MPP+)
induced significantly more toxicity than incubation with
MPP+ during only one of the 24-h periods
(MPP+/control or
control/MPP+). In addition, toxicity after
treatment with MPP+/control was not significantly
different from control/MPP+. Thus, we infer that
most cells surviving the initial 24 h of MPP+ treatment continue to survive for an
additional 24 h if MPP+ is removed from the
media. These data suggest that MPP+-mediated
toxicity is an active process that depends on the continuous presence
of MPP+ and indicate that such active processes
are likely to be present 24 h after incubation with
MPP+. Therefore, most of the following
physiologic studies comparing the effects of MPP+
on 
m and ROS in individual dopaminergic versus nondopaminergic neurons were performed 24 h after treatment. In addition, to
include cells that are in the process of cell death, all cells with
intact somata were used for imaging studies regardless of their neurite morphology.
|
MPP+ Has Minimal Effect on 
m, Whereas Rotenone
Significantly Decreases 
m.
We next examined whether
MPP+ mediates its selective toxicity to
dopaminergic neurons by decreasing 
m. We compared the effect of
MPP+ on 
m with that of 20 nM rotenone, a dose that
induced significantly less toxicity to dopaminergic neurons than 5 µM
MPP+. We hypothesized that if
MPP+ exerted its toxicity primarily by inhibiting
complex I, then MPP+ would depolarize 
m to
a greater extent than rotenone. To estimate 
m, we used JC-1
fluorescence, which is sensitive to changes in 
m over a
physiologic range (Reers et al., 1995
). In addition, JC-1 resists
quenching, and its ratiometric properties minimize artifacts
encountered using single-wavelength dyes. The mean JC-1 ratios were
lower in control dopaminergic neurons than in control nondopaminergic
neurons by 13% (Fig. 2, A versus D). The
JC-1 ratios in each treatment group were normalized to the ratios in the untreated control group to appreciate the relative effects of
treatment on 
m in each cell type (Fig. 2J). After 24 h of MPP+ exposure, the JC-1 ratio in dopaminergic
neurons decreased by 12% but did not change significantly in
nondopaminergic neurons. In contrast, rotenone significantly decreased
the JC-1 ratio in both dopaminergic and nondopaminergic neurons by 26 and 25%, respectively. As a control, 1 µM FCCP was used to
depolarize the mitochondria and decreased the JC-1 ratios by 52% in
dopaminergic and 58% in nondopaminergic neurons. These data suggest
that although 5 µM MPP+ is more toxic to
dopaminergic neurons than 20 nM rotenone, it has less effect on complex
I activity.
|
MPP+ Does Not Increase Superoxide Levels Selectively in
Dopaminergic Neurons.
To determine whether
MPP+ increased superoxide, we used real-time Et
fluorescence measurements in living dopaminergic and nondopaminergic neurons (Bindokas et al., 1996
). HEt has been shown to be oxidized rapidly to Et by reacting with superoxide but not with
O2,
H2O2, HOCl, or
peroxynitrite (Bindokas et al., 1996
). Incubation with MPP+ (5 µM) had no effect on superoxide in
either dopaminergic or nondopaminergic neurons when Et fluorescence was
monitored acutely 3 to 6 min and 4 h after the addition of
MPP+ (Fig. 3A).
After 24 h, a slight increase in superoxide was noted in
nondopaminergic neurons (30%), which was a significantly different effect from that on dopaminergic neurons. We also compared the effects
of MPP+ on superoxide with those of rotenone, a
potent complex I inhibitor. Rotenone (20 nM) increased superoxide in
nondopaminergic neurons but did not affect superoxide in dopaminergic
neurons acutely (Fig. 3B). After 24 h, no persistent effect of
rotenone on the superoxide level were noted in either dopaminergic or
nondopaminergic neurons. Therefore, at low doses that are still
sufficient to kill dopaminergic neurons, neither
MPP+ nor rotenone increased superoxide in
dopaminergic neurons.
|
MPP+ Has No Detectable Effect on GSH.
To provide
additional evidence that MPP+ selectively kills
dopaminergic neurons independent of oxidative stress, we examined the
effects of MPP+ on GSH levels.
MPP+-induced mitochondrial dysfunction can also
inhibit GSH synthesis by decreasing ATP levels (Di Monte et al., 1987
;
Mithofer et al., 1992
). Nevertheless, MPP+ (5 µM) did not change GSH levels in either dopaminergic or
nondopaminergic neurons after 24 h (Fig.
4), as assessed from MCB fluorescence. Although MPP+ may selectively deplete
mitochondrial GSH, the mitochondrial pool is usually maintained at the
expense of cytosolic levels (Meredith and Reed, 1982
). Therefore, a
significant loss of GSH from the mitochondria should lead to decreased
cytosolic levels and would be reflected in the total cellular levels
that we measured. BSO, a specific inhibitor of the rate-limiting enzyme
in glutathione synthesis,
-glutamylcysteine synthetase, was used as
a positive control for decreased GSH levels. BSO (10 µM) decreased
GSH levels in dopaminergic and nondopaminergic neurons to 54 and 30%
of control values, respectively by 24 h. Glia were noted to have
comparatively higher levels of GSH than neurons (data not shown), which
is consistent with previous observations (Rice and Russo-Menna, 1998
).
|
| |
Discussion |
|---|
|
|
|---|
Role of Complex I Inhibition in MPP+ Toxicity: Effects
on 
m, ROS, and GSH.
Our data show that
MPP+ caused minimal dissipation of 
m in
dopaminergic neurons at a dose (5 µM) that produced selective toxicity (Fig. 2). This finding is consistent with Lotharius et al.
(1999)
, who found that low doses of MPP+ produced
only a late transient change in 
m in dopaminergic neurons, as
measured by rhodamine 123. In addition, a less toxic dose of the
specific complex I inhibitor rotenone (20 nM) decreased 
m to a
greater extent than MPP+. Therefore,
depolarization of 
m is not the primary mechanism of
MPP+ toxicity.

m,
superoxide, or GSH occurred transiently in any given cell but triggered
an irreversible cascade of events that subsequently led to cell death, they might have been difficult to detect at any given point. However, the time course of cell death induced by MPP+
(Table 1) indicates that the continued presence of
MPP+ is necessary for cells to reach the point of
our morphological criteria of cell death, and hence intracellular
events that are critical for committing cells to the death process must
also be present up until this point. Second, our observation that a
significant proportion of dopaminergic neurons at 24 h already
showed changes in nuclear morphologies but still had intact cell bodies
(data not shown) indicates that our sample population included a large number of dopaminergic neurons that were in the process of dying. Consistent with this, the analysis of data from individual dopaminergic neurons did not show bimodal distribution of 
m, superoxide, and
GSH in both controls and dopaminergic neurons treated with MPP+ (data not shown). Bimodal distribution would
be expected if there were populations of cells undergoing
MPP+-induced changes and those that were not.
Third, Budd et al. (1997)
m. Et fluorescence did not increase in dopaminergic
neurons (Fig. 3B) despite mitochondrial depolarization by rotenone
(Fig. 2J), demonstrating the absence of a false-positive increase in Et
fluorescence from the mitochondrial depolarization in our system.
Second, Et fluorescence increased in nondopaminergic neurons after
24 h of 5 µM MPP+ treatment (Fig. 3A)
without any change in 
m (Fig. 2J), suggesting that Et
fluorescence changes independent of mitochondrial depolarization.
Mechanisms of MPP+ Toxicity to Dopaminergic
Neurons.
The apparently contradictory findings in the literature
regarding the involvement of mitochondrial disruption and ROS
generation in MPTP or MPP+ toxicity may be due to
differences between high and low doses and between MPTP and
MPP+, as well as differences among model systems.
Most of the data supporting the role of ROS and mitochondrial
dysfunction in MPP+ toxicity come from
experiments using high doses of MPP+ in
nondopaminergic, and often nonneuronal, cell types or from indirect
evidence obtained in vivo. In vivo, the conversion of MPTP to
MPP+ may represent a significant source of ROS
including H2O2 and superoxide (Lai et al., 1993
). In addition, glutaminergic neurons projecting from cortex to striatum may contribute to the toxicity through excitotoxicity and oxidative stress (Sonsalla et al., 1998
).
Studies that specifically examined dopaminergic cells showed that low
doses of MPP+ produced minimal ROS generation
(Choi et al., 1999
). Dopaminergic neurons cultured from Cu/Zn-SOD
transgenic mice are not resistant to MPP+
toxicity compared with controls (Sanchez-Ramos et al., 1997
). In
addition, NO synthase inhibitors have little protective effect against
MPP+ toxicity in vitro (Lotharius et al., 1999
;
Choi et al., 1999
). The potent ROS scavenger C3
carboxyfullerene blocked the toxicity of 6-hydroxydopamine in
mesencephalic cultures completely but offered only partial protection
against MPP+ (Lotharius et al., 1999
). A variety
of other antioxidants also failed to protect against
MPP+ in dopaminergic cells (Sanchez-Ramos et al.,
1988
; Choi et al., 1999
). Taken together, these studies suggest that
the selective toxicity of a low dose of MPP+ to
dopaminergic neurons in vitro is not mediated through complex I
inhibition leading to depolarization of 
m or the generation of
ROS. Although superoxide may be elevated under some conditions, such
elevation is not necessary for either MPP+ or
rotenone to induce dopaminergic neuronal death.

m, decreased ATP synthesis
due to complex I inhibition may still contribute to
MPP+ toxicity. To maintain 
m, cells may
decrease or even reverse flux through the ATP synthase (Budd and
Nicholls, 1996
-ketoglutarate dehydrogenase (Mizuno et al., 1987a
m and generation of ROS, is not
the primary mechanism by which MPP+
preferentially kills dopaminergic neurons, although they may occur in
certain situations as epiphenomena. Rather, further research into how
low doses of MPP+ induce the selective death of
dopaminergic neurons independent of mitochondrial depolarization will
be useful. Such studies may also provide insight into the mechanism of
nigrostriatal degeneration in PD.
| |
Acknowledgments |
|---|
We thank Dr. B. Weir for use of his microscope for some of the experiments and Dr. J. Brorson for helpful comments.
| |
Footnotes |
|---|
Received September 21, 1999; Accepted May 4, 2000
This research was supported by the Brain Research Foundation, Louis R. Block Fund, National Parkinson Foundation, Parkinson Disease Foundation, United Parkinson Foundation, and U.S. Public Health Service Grant NS07113.
Send reprint requests to: Un Jung Kang, M.D., MC 2030, S225B, Department of Neurology, The University of Chicago, 5841 S. Maryland Ave., Chicago, IL 60637. E-mail: u-kang{at}uchicago.edu
| |
Abbreviations |
|---|
PD, Parkinson's disease;
MPP+, 1-methyl-4-phenylpyridinium;

m, mitochondrial membrane potential;
GSH, reduced glutathione;
MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine;
NO, nitric oxide;
SOD, superoxide dismutase;
DAB, 3,3'-diaminobenzidine tetrahydrochloride;
DMEM, Dulbecco's modified Eagle's medium;
DMSO, dimethyl sulfoxide;
NFP, neurofilament protein 200;
TH, tyrosine hydroxylase;
JC-1, 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanine
iodide;
HEt, hydroethidine;
Et, ethidium;
MCB, monochlorobimane;
BSO, L-buthionine-[S,R]sulfoximine;
FCCP, carbonyl cyanide
p-trifluoromethoxy-phenylhydrazone;
DIC, differential
interference contrast;
ROS, reactive oxygen species;
Cu/Zn-SOD, copper/zinc form of SOD.
| |
References |
|---|
|
|
|---|

changes in intact cells: Implications for studies on mitochondrial functionality during apoptosis.
FEBS Lett
411:
77-82[Medline].This article has been cited by other articles:
![]() |
R. M. LoPachin and T. Gavin Response to "Paraquat: The Red Herring of Parkinson's Disease Research" Toxicol. Sci., May 1, 2008; 103(1): 219 - 221. [Full Text] [PDF] |
||||
![]() |
J. R. Richardson, W. M. Caudle, T. S. Guillot, J. L. Watson, E. Nakamaru-Ogiso, B. B. Seo, T. B. Sherer, J. T. Greenamyre, T. Yagi, A. Matsuno-Yagi, et al. Obligatory Role for Complex I Inhibition in the Dopaminergic Neurotoxicity of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Toxicol. Sci., January 1, 2007; 95(1): 196 - 204. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Richardson, Y. Quan, T. B. Sherer, J. T. Greenamyre, and G. W. Miller Paraquat Neurotoxicity is Distinct from that of MPTP and Rotenone Toxicol. Sci., November 1, 2005; 88(1): 193 - 201. [Abstract] [Full Text] [PDF] |
||||
![]() |
G.-R. Kweon, J. D. Marks, R. Krencik, E. H. Leung, P. T. Schumacker, K. Hyland, and U. J. Kang Distinct Mechanisms of Neurodegeneration Induced by Chronic Complex I Inhibition in Dopaminergic and Non-dopaminergic Cells J. Biol. Chem., December 10, 2004; 279(50): 51783 - 51792. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Weissmann, N. Ebert, M. Ahrens, H. A. Ghofrani, R. T. Schermuly, J. Hanze, L. Fink, F. Rose, J. Conzen, W. Seeger, et al. Effects of Mitochondrial Inhibitors and Uncouplers on Hypoxic Vasoconstriction in Rabbit Lungs Am. J. Respir. Cell Mol. Biol., December 1, 2003; 29(6): 721 - 732. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Crocker, P. D. Smith, V. Jackson-Lewis, W. R. Lamba, S. P. Hayley, E. Grimm, S. M. Callaghan, R. S. Slack, E. Melloni, S. Przedborski, et al. Inhibition of Calpains Prevents Neuronal and Behavioral Deficits in an MPTP Mouse Model of Parkinson's Disease J. Neurosci., May 15, 2003; 23(10): 4081 - 4091. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. B. Sherer, R. Betarbet, A. K. Stout, S. Lund, M. Baptista, A. V. Panov, M. R. Cookson, and J. T. Greenamyre An In Vitro Model of Parkinson's Disease: Linking Mitochondrial Impairment to Altered alpha -Synuclein Metabolism and Oxidative Damage J. Neurosci., August 15, 2002; 22(16): 7006 - 7015. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. C. Waldmeier, J.-J. Feldtrauer, T. Qian, and J. J. Lemasters Inhibition of the Mitochondrial Permeability Transition by the Nonimmunosuppressive Cyclosporin Derivative NIM811 Mol. Pharmacol., July 1, 2002; 62(1): 22 - 29. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||